These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38431222)

  • 21. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
    Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
    De A; Das S; Dhoot D; Sarda A
    Indian J Dermatol; 2020; 65(5):396-400. PubMed ID: 33165422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.
    Verbenko DA; Karamova AE; Artamonova OG; Deryabin DG; Rakitko A; Chernitsov A; Krasnenko A; Elmuratov A; Solomka VS; Kubanov AA
    J Pers Med; 2020 Dec; 11(1):. PubMed ID: 33383665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
    Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.
    Gelfand JM; Shin DB; Armstrong AW; Tyring SK; Blauvelt A; Gottlieb S; Lockshin BN; Kalb RE; Fitzsimmons R; Rodante J; Parel P; Manyak GA; Mendelsohn L; Noe MH; Papadopoulos M; Syed MN; Werner TJ; Wan J; Playford MP; Alavi A; Mehta NN
    JAMA Dermatol; 2022 Dec; 158(12):1394-1403. PubMed ID: 36129688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
    Okubo Y; Ohtsuki M; Komine M; Imafuku S; Kassir N; Petric R; Nemoto O
    J Dermatol; 2021 Nov; 48(11):1652-1664. PubMed ID: 34396569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
    Oehrl S; Prakash H; Ebling A; Trenkler N; Wölbing P; Kunze A; Döbel T; Schmitz M; Enk A; Schäkel K
    J Dermatol Sci; 2017 Aug; 87(2):110-115. PubMed ID: 28499587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
    Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
    J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
    Strand V; Fiorentino D; Hu C; Day RM; Stevens RM; Papp KA
    Health Qual Life Outcomes; 2013 May; 11():82. PubMed ID: 23663752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
    Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; Suárez-Pérez JA; Armesto S; Rivera R; Herrera-Acosta E; Herranz P; Martín I; Montesinos E; Hospital M; Vilarrasa E; Ferran M; Ruiz-Villaverde R; Sahuquillo-Torralba A; Ruiz-Genao DP; Pérez-Barrio S; Muñoz C; Llamas M; Valentí F; Mitxelena MJ; López-Ferrer A; Carretero G; Vidal D; Mollet J; Belinchón I; Carrascosa JM
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2821-2829. PubMed ID: 32271966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis.
    Srivastava D; Krishna A; David A
    Indian J Dermatol; 2023; 68(4):393-398. PubMed ID: 37822410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J; Nelson E; Keegan BR
    J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, tolerability and patient's satisfaction for the treatment of moderate to severe plaque psoriasis with apremilast in the real-life setting of Campania region, Italy.
    Licata G; Tancredi V; Gambardella A; Megna M; Fabbrocini G; Raimondo A; Lembo S; Ligrone L; Cusano F; Argenziano G
    Ital J Dermatol Venerol; 2023 Dec; 158(6):452-456. PubMed ID: 37721774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.